bioRxivMolecular BiologyPreprint
Profibrotic priming of airway cell types and drug responses in early-stage idiopathic pulmonary fibrosis
Robert Lorenz ChuaiD, Carmen Veith, Marc Andre SchneideriD, Katharina JechowiD, Elizabeth Chang Xu, Michael KreuteriD, Agnes W. BootsiD, Roland EilsiD, Nicolas Carlos KahniD, Christian ConradiD
Abstract
Early genetic studies hinted the role of airway epithelial cells in the development of idiopathic pulmonary fibrosis (IPF), while recent single-cell RNA sequencing (scRNA-seq) atlases utilized explant IPF lungs and therefore represent late-stage disease. Here, we used air liquid interface (ALI) cultures of primary cells taken from the subsegmental bronchi of newly diagnosed IPF patients, reflecting early-stage fibrosis, to interrogate the transcriptional landscape of the airway mucosa. Profiling of 129,986 cells identified a shared proinflammatory state in epithelial cells and an early activation state of fibroblasts. Moreover, IPF basal cells initiated awry repair mechanisms and primed the airway mucosa for TGF-{beta} activation. Treatment with nintedanib, pirfenidone, both established antifibrotic drugs, and saracatinib, an Src kinase inhibitor that can limit IPF progression, only significantly affected certain IPF signatures. This study provides insight into the early disease mechanisms of IPF and may serve as a resource to further investigate pharmacological inhibition effects.
- organism: human
- assay: scRNA-seq
- research focus: cell type annotation
- research focus: differential expression
- approach: statistical model
- Citations
- 1
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Airway Basal Cells show a dedifferentiated KRT17high Phenotype and promote Fibrosis in Idiopathic Pulmonary Fibrosis
B. Jaeger, J. C. Schupp, … A. Prasse·bioRxiv·Sep 4, 2020
- Alveolar niche disruption and aberrant epithelial reprogramming are early hallmarks of idiopathic pulmonary fibrosis
A. Justet, Venerino E. Poletti, … Naftali Kaminski·bioRxiv·May 30, 2026
- Modeling cell-cell interactions to advance drug discovery in Idiopathic Pulmonary Fibrosis
Chandani Sen, Justin Langerman, … Brigitte N. Gomperts·bioRxiv·Jun 25, 2026
- NINTEDANIB AND PIRFENIDONE AFFECT GROWTH AND DIFFERENTIATION OF HUMAN ALVEOLAR TYPE 2 CELLS
Alexey V. Bazarov, Andrea Serra-Marques, … Paul J. Wolters·bioRxiv·Mar 3, 2026
- Recapitulating idiopathic pulmonary fibrosis related alveolar epithelial dysfunction in an iPSC-derived air-liquid interface model
E. Schruf, V. Schroeder, … J. P. Garnett·bioRxiv·Nov 4, 2019
- Modeling of Aberrant Epithelial Reprogramming in Idiopathic Pulmonary Fibrosis using Human Induced Pluripotent Stem Cell-derived Alveolar Organoids
V. Ptasinski, S. J. Monkley, … L. A. Murray·bioRxiv·Jun 15, 2022